About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The search for quality and innovation has always been an inherent part of the activity of the Stroke Research Group and represents the common thread that leads us to excellence and continuous improvement.
In recent years, the Stroke Research Group has established itself as a leader in the management, recruitment and international coordination of multicenter clinical trials, as well as in the development of patents for new thrombectomy devices and the creation of new technological solutions and digital platforms to improve the diagnosis, treatment and follow-up of stroke patients. Robust strategic alliances have also been consolidated with public and private entities that ensure the viability and scalability of the research projects initiated in our group.
The Stroke Research Group is made up of a transversal and multidisciplinary team that shares a common idea: to contribute from its area of knowledge to the care and management of stroke through the effective transfer of knowledge and the complementarity of the processes of clinical research.
IP: Carlos Molina Cateriano Collaborators: Maria Baladas Orti, Ester Sanchez Gavilan, Cristina Guirao Martinez, Marina Jimenez Iglesias, Lidia Garcia Guillamón, Federica Rizzo, Marta Aurora Rubiera del Fueyo, David Rodriguez Luna, Manuel Requena Ruiz, Marta Olive Gadea, Alvaro Garcia Tornel Garcia Camba, Marc Rodrigo Gisbert, Olalla Pancorbo Rosal, Claudia Meza Burgos Funding agency: EUROPEAN COMMISSION Funding: 468090 Reference: HARMONICS_EIT-HEALTH-BP2022 Duration: 01/01/2022 - 31/12/2024
IP: Marc Ribó Jacobi Collaborators: Marta Aurora Rubiera del Fueyo, Carlos Molina Cateriano, Federica Rizzo Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 437334 Reference: CPP2021-008378 Duration: 01/03/2022 - 30/09/2025
IP: Deborah Pareto Onghena Collaborators: Ingrid Galán Cartaña, Herena Eixarch Ahufinger, M Jesus Arevalo Navines, Neus Mongay Ochoa, Giorgio Colangelo Funding agency: Instituto de Salud Carlos III Funding: 87120 Reference: PI22/01709 Duration: 01/01/2023 - 31/12/2025
IP: Mª Ángeles Muchada López Collaborators: Carlos Molina Cateriano, Alvaro Garcia Tornel Garcia Camba, Marc Rodrigo Gisbert Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI22/01928 Duration: 01/01/2023 - 31/12/2025
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The study analyzes a new therapeutic strategy in high-risk patients that could influence future international clinical guidelines
The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.
